Bio-Path Holdings to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Rhea-AI Summary

Bio-Path Holdings, a biotechnology firm, is set to present a corporate overview at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020, at 11:30 a.m. ET. CEO Peter H. Nielsen will lead the presentation. The company specializes in developing targeted nucleic acid cancer drugs utilizing its proprietary DNAbilize™ technology. Its lead candidate, prexigebersen (BP1001), is in a Phase 2 study for blood cancers and is also under FDA consideration for solid tumors. Follow-up candidate BP1002 targets lymphoma and solid tumors.

HOUSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter H. Nielsen, Chief Executive Officer, will present a corporate overview at the upcoming virtual H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020 at 11:30 a.m. ET.

A live webcast of the presentation can be accessed under “Events” in the Media section of the Company’s website at www.biopathholdings.com.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize^®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and is under consideration by the FDA to commence Phase 1 studies in solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, where it will be evaluated in lymphoma and solid tumors clinical studies.

For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:

Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com 

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369

FAQ

When will Bio-Path Holdings present at the H.C. Wainwright conference?

Bio-Path Holdings will present on September 16, 2020, at 11:30 a.m. ET.

Who is the CEO of Bio-Path Holdings?

The CEO of Bio-Path Holdings is Peter H. Nielsen.

What is the lead product candidate of Bio-Path Holdings?

The lead product candidate is prexigebersen (BP1001), targeting blood cancers.

What technology does Bio-Path Holdings use for its drug development?

Bio-Path Holdings uses its proprietary DNAbilize™ liposomal delivery and antisense technology.

What are the future prospects for prexigebersen?

Prexigebersen (BP1001) is in a Phase 2 study for blood cancers and is considered by the FDA for Phase 1 studies in solid tumors.

What is the second candidate developed by Bio-Path Holdings?

The second candidate, BP1002, targets the Bcl-2 protein and will be evaluated in lymphoma and solid tumor studies.